Journal of Virus Eradication最新文献

{"title":"Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand.","authors":"Nawarat Posuwan, Rujipat Wasitthankasem, Napaporn Pimsing, Wijittra Phaengkha, Saranya Ngamnimit, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Maneerat Raksayod, Yong Poovorawan","doi":"10.1016/j.jve.2024.100577","DOIUrl":"https://doi.org/10.1016/j.jve.2024.100577","url":null,"abstract":"<p><p>Chronic hepatitis B (HBV) and C (HCV) are major health challenges in Thailand, with Phetchabun province, a known HCV-endemic area, being a key target for elimination efforts. This study aimed to assess HBV prevalence and identify associated risk factors in this province. Data was collected from three cross-sectional population studies: (1) adults in 2015 (n = 1,667, age 30-64 years), (2) young adults in 2017 (n = 1,453, age 18-30 years), both from high HCV-endemic districts, and (3) a province-wide study in 2018 (n = 4,769, age 35-64 years). Plasma samples were tested for HBsAg using the ARCHITECT assay. Results showed HBsAg seropositivity in 3.1 % of young adults in high-endemic districts, with significant associations with age, education, injecting drug use, and MSM behavior. Among adults, HBsAg prevalence was 5.9 %, linked to age and family liver disease history. Province-wide, 6.3 % of adults tested positive, with factors like gender and history of blood donation playing significant roles. Notably, age and blood donation were protective factors against HBV in adults. Analysis revealed a moderate HBV prevalence in those born before Thailand Expanded Program on Immunization (EPI) program, while those born after had rates below 1 %. The findings emphasize distinct HBV transmission patterns in different age groups, influenced by social and behavioral shifts. This knowledge is crucial for effective hepatitis elimination strategies in the Phetchabun province and nationwide.</p>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"100577"},"PeriodicalIF":3.5,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relatively high interest but limited active engagement in HIV cure research: Awareness, interest, and information-seeking among affected communities in the Netherlands.","authors":"Maaike A J Noorman, John B F de Wit, Tamika A Marcos, Sarah E Stutterheim, Thijs Albers, Kai J Jonas, Chantal den Daas","doi":"10.1016/j.jve.2024.100570","DOIUrl":"https://doi.org/10.1016/j.jve.2024.100570","url":null,"abstract":"<p><strong>Background: </strong>Community engagement is important for inclusive HIV cure development. This study evaluates current engagement in HIV cure research among affected communities in the Netherlands by analyzing awareness, interest, and information-seeking behavior. It also identifies participant characteristics and HIV-related illness perceptions linked to each engagement stage.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted from July 2023 to March 2024, involving 499 people with HIV and 578 individuals without HIV, including partners and gay, bisexual, and other men who have sex with men. Multivariate regression analyses examined the relationships between participant characteristics, HIV-related illness perceptions, and three outcomes: awareness, interest, and information-seeking.</p><p><strong>Results: </strong>The mean awareness was 3.08 (SD = 0.99) interest was higher at 3.67 (SD = 0.85), while the information-seeking frequency was lower at 2.33 (SD = 0.97). Higher awareness was seen in older participants, non-cisgender men, and those with increased perceived control and comprehensibility of HIV. Interest in cure research was higher among people with HIV, those with a migration background, individuals with steady partner(s), and those experiencing greater HIV-related concerns, negative HIV-related emotions, and better HIV comprehension. Information-seeking frequency was greater among people with HIV, those with a bachelor's degree, individuals from a migration background, those with steady partner(s), and those perceiving more severe HIV-related symptoms, and heightened concerns and negative emotions about HIV.</p><p><strong>Conclusion: </strong>While moderate awareness exists, engagement remains passive with limited information-seeking; however, significant interest in a cure underscores the need for enhanced communication efforts to foster inclusive HIV cure development.</p>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"100570"},"PeriodicalIF":3.5,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients.","authors":"Jiayi Wang, Lingyao Du, Dongmei Zhang, Chen Zhou, Yilan Zeng, Miao Liu, Xing Cheng, Xiaona Song, Han Chen, Ning Han, Enqiang Chen, Hong Tang","doi":"10.1016/j.jve.2024.100571","DOIUrl":"10.1016/j.jve.2024.100571","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.</p><p><strong>Methods: </strong>In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China. Patients included adults with with CHC and any genotype (GT), with or without cirrhosis, hepatocellular carcinoma (HCC), HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection. Patients were administered SOF/VEL (400/100 mg) ± ribavirin (RBV) once daily for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12). Adverse events (AEs) were evaluated during treatment.</p><p><strong>Results: </strong>The study included 483 patients with HCV genotypes 1, 2, 3, 6 and uncertain ones. Among them, 35.4 % (171/483, ITT) and 36.7 % (166/452, mITT) received SOF/VEL + RBV. At the end of treatment , 99.2 % (ITT, 479/483) and 99.1 % (mITT, 448/452) of patients had undetectable HCV RNA. SVR12 rates were 92.8 % [intention to treat (ITT), 448/483] and 99.1 % [modified ITT (mITT), 448/452]. In the mITT analysis, SVR12 for patients with HCV GT3b, those with cirrhosis or HCC, and those coinfected with HBV/HIV was 99.2 % (130/131), 99.4 % (168/169), and 97.6 % (40/41), respectively. The albumin-bilirubin (ALBI) (-3.01 <i>vs.</i> -3.18 <i>P</i> < 0.001), Fibrosis-4 (FIB4) Index (2.53 <i>vs.</i> 1.88, <i>P</i> = 0.004) and AST to Platelet Ratio Index (APRI) (0.99 <i>vs.</i> 0.44, <i>P</i> < 0.001) scores showed a significant decrease from baseline to SVR12. No patients experienced grade 3-5 AEs.</p><p><strong>Conclusions: </strong>Although a high proportion of patients included in this study had HCV GT3b, cirrhosis, HCC, or HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection, SOF/VEL ± RBV was highly effective and well tolerated in Chinese patients with CHC.</p>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"100571"},"PeriodicalIF":3.5,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study","authors":"Jozefien De Clercq ,&nbsp;Marie-Angélique De Scheerder ,&nbsp;Sophie Vanherrewege ,&nbsp;Els Caluwé ,&nbsp;Nathalie Moreels ,&nbsp;Danny Delooze ,&nbsp;Annemieke Dhondt ,&nbsp;Marc Coppens ,&nbsp;Stefaan J. Vandecasteele ,&nbsp;Sabine D. Allard ,&nbsp;Coca Necsoi ,&nbsp;Stéphane De Wit ,&nbsp;Sarah Gerlo ,&nbsp;Linos Vandekerckhove","doi":"10.1016/j.jve.2024.100392","DOIUrl":"10.1016/j.jve.2024.100392","url":null,"abstract":"<div><h3>Background</h3><div>The events during acute HIV infection (AHI) set the stage for the subsequent course of the disease. Early initiation of antiretroviral therapy (ART) has been associated with favorable immunovirological outcomes, yet the precise impact of ART timing during AHI remains unclear, particularly on lymphoid tissues.</div></div><div><h3>Materials and methods</h3><div>The ACS cohort is a prospective cohort study in Belgium, collecting longitudinal clinical data and human bodily material (HBM) from people diagnosed and treated during AHI. The aim of the cohort is to study the impact of ART initiation during AHI on HIV reservoir and immune dysfunction in peripheral blood and anatomical sanctuary sites, as well as its effect on the gut microbiome. The cohort consists of two HBM sampling trajectories: one limited (blood, stool and leukapheresis) and a more extensive one (blood, stool, leukapheresis, colonoscopy, inguinal lymph node excision and lumbar puncture). Here we describe the baseline characteristics, immunovirological outcomes, safety and tolerability of HBM sampling.</div></div><div><h3>Results</h3><div>Between March 2016 and April 2024, 47 participants were enrolled, predominantly men who have sex with men (MSM), with a median age of 36 years [IQR 30–43.5]. Almost 90 % of participants initiated ART within 72 h after study inclusion, irrespective of HBM sampling trajectory. The timing of ART initiation according to the Fiebig stage did not significantly impact immune recovery (CD4/CD8 ratio ≥1) or the time to viral suppression. Approximately 40 % of participants opted for the extensive HBM sampling trajectory during AHI. However, the participation rate for the extensive trajectory decreased by nearly half at the longitudinal follow-up timepoint. In general, study-related procedures were safe and well-tolerated, with limited procedure-related adverse events (AEs). Inguinal lymph node excision was associated with the highest AE rate, in line with previous reports.</div></div><div><h3>Conclusions</h3><div>Our findings reaffirm the beneficial effect of ART initiation during AHI on long term immunovirological outcomes, regardless of Fiebig stage at treatment initiation. Additionally, we demonstrate that the collection of HBM during and longitudinally after AHI is safe and feasible, without compromising time to ART initiation. Cohorts that integrate comprehensive clinical data with high-quality HBM samples are essential to longitudinally study the impact of early ART on reservoir dynamics and immune responses across various anatomical sites after AHI.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100392"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk","authors":"Karine Dubé ,&nbsp;Thomas J. Villa ,&nbsp;William Freshwater ,&nbsp;Brittney Mauk ,&nbsp;Annette Rid ,&nbsp;Michael J. Peluso","doi":"10.1016/j.jve.2024.100386","DOIUrl":"10.1016/j.jve.2024.100386","url":null,"abstract":"<div><div>Analytical treatment interruptions (ATIs) are widely used to evaluate HIV cure-related research interventions. However, sex partners of cure-related trial participants might be at risk of acquiring HIV during ATIs. Addressing this risk is key to ensuring the continued success of trials involving ATIs and offer greater acceptability across multiple trials sites. In 2022, the Advancing Clinical Therapeutics Globally (ACTG) Network convened a Partner Protections Working Group (PPWG) to update the 2020 HIV transmission risk toolkit developed by Peluso and colleagues. In our review of the original toolkit, we identified new challenges and needs at the participant, partner and study levels, as well as new evidence on measures to address these needs and more advanced ethical thinking on partner protections in HIV cure-related trials with ATIs. Based on these findings, we developed an updated toolkit that will provide trial participants and their partners with better support to address new and unfamiliar situations and protect partners from undue harm. We present this toolkit, make it available as a resource for cure-related trials with ATIs and discuss possible future directions.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100386"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2055664024000232/pdfft?md5=4998fea798603048df3d77fc61673ab9&pid=1-s2.0-S2055664024000232-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccines coverage and associated factors among children aged 12–23 months in the Pawie district, Ethiopia: A cross-sectional study","authors":"Fekiahmed Salah ,&nbsp;Chernet Tafere ,&nbsp;Lemessa Jira Ejigu ,&nbsp;Fikir Tadesse ,&nbsp;Azeb Gedif ,&nbsp;Sileshi Mulatu","doi":"10.1016/j.jve.2024.100391","DOIUrl":"10.1016/j.jve.2024.100391","url":null,"abstract":"<div><h3>Background</h3><div>Although access to vaccines for children is increasing at healthcare facilities, outbreaks of vaccine preventable diseases and deaths have been reported in different areas of the Benishangul Gumuz region, in Ethiopia. Various interventions have been designed to provide vaccines for each child at an appropriate age. Still there is limited information on full vaccination coverage and associated factors among children aged 12–23 months in the Benishangul-Gumuz region, particularly in the Pawie district.</div></div><div><h3>Method</h3><div>A community-based cross-sectional study design was used from April, 1–30, 2022 among 750 participants. Study populations were selected using a simple random sampling technique. Data was collected using structured questionnaires. Data was coded and entered into the SPSS Statistics 23.0. Bi-variable and multivariate logistic regression analyses were used to assess factors associated with the children vaccination status. Variables with p-value &lt;0.05 were considered significantly associated with the outcome variable.</div></div><div><h3>Result</h3><div>The results of this study revealed that 542 (72.3 %) (95 % CI: 68.9, 75.2) of the children were fully vaccinated. Factors significantly associated with full vaccination coverage included employed mothers (AOR = 0.53, 95 % CI: 0.29, 0.95), antenatal care (ANC) follow-up (AOR = 1.74, 95 % CI: 1.00, 3.03), post-natal care (PNC) follow-up (AOR = 6.19, 95 % CI: 3.62, 10.56), health institution delivery (AOR = 4.70, 95 % CI: 1.90, 11.66), birth order of children (AOR = 3.63, CI: 2.00, 6.59), maternal tetanus toxoid (TT) vaccination (AOR = 3.05, CI: 1.36, 6.86) and knowledge of vaccination schedule (AOR = 2.49, 95 % CI: 1.19, 5.21).</div></div><div><h3>Conclusions</h3><div>This study revealed that among children aged 12–23 months, full vaccination coverage was notably low. Factors significantly associated with higher rates of full vaccination included mothers’ occupation, attendance at ANC visits, PNC visits, birth order of children, place of delivery, maternal awareness of vaccination schedules, and maternal TT vaccination status. These findings highlight the multifaceted influences of maternal characteristics, healthcare use patterns, and maternal knowledge on childhood vaccination in this population.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100391"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression","authors":"Caterina Tramontozzi ,&nbsp;Anna Riccio ,&nbsp;Silvia Pauciullo ,&nbsp;Simone La Frazia ,&nbsp;Antonio Rossi ,&nbsp;M. Gabriella Santoro","doi":"10.1016/j.jve.2024.100387","DOIUrl":"10.1016/j.jve.2024.100387","url":null,"abstract":"<div><div>Coronaviruses (CoV), zoonotic viruses periodically emerging worldwide, represent a constant potential threat to humans. To date, seven human coronaviruses (HCoV) have been identified: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1, globally circulating in the human population (seasonal coronaviruses, sHCoV), and three highly-pathogenic coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2. Although sHCoV generally cause only mild respiratory diseases, severe complications may occur in specific populations, highlighting the need for broad-spectrum anti-coronavirus drugs. Herein we show that indomethacin (INDO), a non-steroidal anti-inflammatory drug widely used in the clinic for its potent anti-inflammatory and analgesic properties, effectively inhibits the replication of <em>Alpha-</em>coronavirus HCoV-229E and <em>Beta-</em>coronavirus HCoV-OC43 in human lung-derived cells. Indomethacin does not interfere with HCoV binding or entry into target cells, but acts at late stages of the virus life cycle, inhibiting viral RNA synthesis and infectious viral particles production. Although INDO anti-inflammatory action is mediated by blocking cyclooxygenase-1 and -2 (COX-1/2) enzymatic activity, the antiviral effect appears to be cyclooxygenase-independent and is not mimicked by the potent COX-1/2 inhibitor aspirin. Interestingly we found that both seasonal HCoVs markedly (&gt;100 fold) induce the expression of the pro-inflammatory mediator COX-2 in lung cells; notably, INDO-treatment was found to effectively inhibit virus-induced COX-2 expression at the transcriptional level, revealing an additional mechanism to prevent COX-2-mediated inflammatory reactions in HCoV-infected lung cells, besides COX activity inhibition. Altogether the results indicate that indomethacin, possessing both potent anti-inflammatory properties and a direct antiviral activity against HCoV, could be effective in the treatment of <em>Alpha-</em> and <em>Beta-</em>coronavirus infections.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100387"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial 10.3","authors":"","doi":"10.1016/j.jve.2024.100390","DOIUrl":"10.1016/j.jve.2024.100390","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100390"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs","authors":"Shana Yi ,&nbsp;David Truong ,&nbsp;Brian Conway","doi":"10.1016/j.jve.2024.100388","DOIUrl":"10.1016/j.jve.2024.100388","url":null,"abstract":"<div><h3>Background</h3><p>To eliminate hepatitis C (HCV) infection as a public health concern by 2030, there is a need to develop comprehensive programs among key populations such as people who use drugs (PWUD). Two highly effective regimens are available for initial therapy: glecaprevir/pibrentasvir (G/P) given as 3 tablets/day for 8 weeks and sofosbuvir/velpatasvir (S/V) given as 1 tablet/day for 12 weeks. Data evaluating the safety and efficacy comparing one regimen over another in a population of PWUD is limited.</p></div><div><h3>Methods</h3><p>Patients were identified through outreach events. Viremic patients were offered HCV treatment within a multidisciplinary program. This retrospective comparison analysis focuses on the first 120 sequential individuals who chose either treatment and in whom a definitive outcome of treatment was available between March 1, 2019 and February 29, 2024. The primary outcomes of the analysis were cure of HCV infection and its corelates, as well as safety of the individual regimens.</p></div><div><h3>Results</h3><p>We successfully identified 120 within each of the G/P and S/V treatment groups. Of those on G/P, we note 28.3 % female, 20.9 % Indigenous, 70.8 % using fentanyl, and 51.3 % with unstable housing. Of those on S/V, we note 25.8 % female, 20.8 % Indigenous, and 75 % using fentanyl and 56.7 % with unstable housing. Overall, 118 and 115 patients completed therapy on G/P and S/V, respectively. A total of 118 and 115 completed therapy on G/P and S/V, with virologic relapse documented in 3 and 2 participants on G/P and S/V, respectively. The ITT/mITT cure rates for G/P and S/V were 95.0 %/97.4 % and 94.2 %/98.3 %, respectively. There were 5 drug overdose deaths among those who initiated treatment, one on G/P and 4 on S/V. <strong>Conclusion</strong>: We have evaluated two highly effective regimens in a group of inner-city PWUD, with comparable success rates well in excess of 90 %. Our data supports the offer of both options for the treatment of PWUD with HCV infection.</p></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100388"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2055664024000256/pdfft?md5=001f4534cfe32b3ae9c07b3fdb92c2c3&pid=1-s2.0-S2055664024000256-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge and attitude among Bangladeshi healthcare workers regarding the management and infection prevention and control of Nipah virus","authors":"Tariful Islam ,&nbsp;Nur-E-Safa Meem ,&nbsp;Mehedi Hasan ,&nbsp;Archi Mutsuddi ,&nbsp;Alberi Afifa Shifat ,&nbsp;Arpita Goutam ,&nbsp;M. Rashidul Bari ,&nbsp;Fahima Nasrin Eva ,&nbsp;Md Faisal Kabir Rozars ,&nbsp;Sayla Sultana ,&nbsp;Naifa Enam Sarker ,&nbsp;Mohammad Hayatun Nabi ,&nbsp;Mohammad Delwer Hossain Hawlader","doi":"10.1016/j.jve.2024.100389","DOIUrl":"10.1016/j.jve.2024.100389","url":null,"abstract":"<div><h3>Background</h3><p>The Nipah virus (NiV) is a zoonotic pathogen that belongs to the Paramyxoviridae family. It can cause severe respiratory and neurological diseases in humans, with varying clinical symptoms. Recognized as a critical public health concern by the World Health Organization, it requires concerted efforts in research and development to prevent outbreaks.</p></div><div><h3>Methodology</h3><p>An analytical cross-sectional study was conducted on 455 healthcare workers across four major regions in Bangladesh from April 2022 to May 2023. Using multistage convenient sampling and face-to-face interviews with a semi-structured questionnaire, we have examined the level of knowledge, attitudes, and individual perceptions of the preparedness for NiV. Data analysis included univariate and bivariate analyses, followed by binary logistic regression to ascertain the association with demographic factors.</p></div><div><h3>Results</h3><p>The study identified a gender disparity favoring female healthcare workers (HCWs). Approximately 46.15 % of participants demonstrated a good knowledge about NiV, with doctors showing significantly higher knowledge odds (OR = 5.197, p &lt; 0.001). Interestingly, graduate and post-graduate education levels did not yield a statistically significant correlation with knowledge. Specific training received was positively associated with knowledge levels (OR = 1.832, p = 0.014), highlighting the gap in routine infection prevention education. Regional differences were notable, with participants from Chittagong having a lower level of knowledge compared to Dhaka (OR = 0.307, p = 0.004). Attitudes towards NiV were predominantly positive, although higher education inversely correlated with positive attitudes, suggesting a potential gap between theoretical knowledge and practical attitudes.</p></div><div><h3>Conclusion</h3><p>While the attitude towards NiV is generally positive among Bangladeshi HCWs, there is a need to enhance knowledge levels, especially in primary care settings and certain regions. To effectively prepare for NiV outbreaks, it is crucial to prioritize continuous education and practical training. The study underscores the importance of implementing uniform educational strategies to equip HCWs across all categories and regions with adequate NiV knowledge and preparedness.</p></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 3","pages":"Article 100389"},"PeriodicalIF":3.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2055664024000268/pdfft?md5=651174bdf6c158bb00ea71e5107e7d8b&pid=1-s2.0-S2055664024000268-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}